Who We Are 2017-06-07T16:55:03+00:00

Who We Are

pSivida is a specialty pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. The dedicated team of scientists at pSivida has developed three of the only four products approved by the FDA for the long-term, sustained-release delivery of drug to treat chronic back of the eye diseases.

pSivida is currently in late stage clinical development of a three-year sustained-release fluocinolone acetonide product in the proven Durasert Technology for the treatment of posterior uveitis. Posterior uveitis is a chronic, non-infectious inflammation of the posterior segment of the eye that can lead to blindness. The first Phase 3 study enrolled 129 patients and met its primary endpoint of prevention of recurrence of posterior uveitis at six months with high statistical significance. Data at 12 months from the same study demonstrated sustainability of the treatment effect. The second Phase 3 study completed enrollment of 153 patients in October of 2016 and results are expected late in the 2Q of 2017. pSivida expects to file in the EU during the first half of 2017 and in the U.S. second half of 2017.

pSivida has ongoing collaborations with other pharmaceutical companies to develop sustained-release products to treat retinal diseases and other ocular conditions. pSivida is also working with the Hospital for Special Surgery (HSS) to assess the efficacy of a titanium screw drug implant to treat pain associated with severe osteoarthritis of the knee.

Leadership

Nancy Lurker was appointed pSivida’s President & Chief Executive Officer in September 2016. Ms. Lurker has broad-ranging experience in the pharmaceutical industry and companies serving the pharmaceutical industry, including diverse senior leadership positions. From 2008 to 2015, Ms. Lurker served as President, Chief Executive Officer, and a director of PDI, Inc., a NASDAQ-listed healthcare commercialization company. She successfully rebuilt PDI’s contract sales business, launching numerous pharmaceutical products for multiple companies across diverse therapeutic areas, including ophthalmology, in advance of a sale of that business line to Publicis Healthcare Communications Group. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a multi-billion-dollar product portfolio covering cardiovascular, bone, pain, urology, respiratory, dermatology, biologics, neurology, and metabolic therapeutic areas. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company, now part of IMS Health Holdings, Inc., where she substantially grew revenues and profitability. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory, and women’s health drugs, overseeing the worldwide launch of Detrol® and Detrol® LA, and repositioning Ambien® for revenue growth. She also served as a member of Pharmacia’s U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker serves as a member of the Board of Directors of the privately held Cancer Treatment Centers of America, is Chair for privately held X4 Pharmaceuticals, an immunology oncology company and advisor to Novo A/S. Ms. Lurker previously served as a member of the Boards of Directors of Mallinckrodt Pharmaceuticals, plc (NYSE: MNK) and Auxilium Pharmaceuticals, Inc. (NASDAQ: ENDP). Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

Ms. Jorn’s experience and expertise in corporate licensing, M&A, and alliance management helped her build US and global pharmaceutical businesses across numerous therapeutic areas, including ophthalmology. Most recently, she was EVP and Company Chair at Valeant Pharmaceuticals, and previously served as Chief Marketing Officer at Bausch & Lomb. Earlier, Ms. Jorn was Group VP of Women’s Healthcare and Fertility at Schering Plough. She was also at Johnson & Johnson as the Worldwide VP of Internal Medicine and Early Commercial Input. She began her career at Merck and for more than twenty years held roles of progressive responsibility in a variety of functions including R&D, regulatory, sales, and marketing. Ms. Jorn holds a B.A. in Biochemistry from Rutgers University and an MBA from New York University’s Stern Graduate School of Business Administration.

Dr. Paggiarino joined pSivida from Lpath, a leader in lipid-targeted therapeutics, where he served as Senior Vice President and Chief Development Officer. Prior to joining Lpath, he was Vice President and Therapeutic Unit Head for Retinal Diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical development pipeline through regulatory approvals worldwide. Dr. Paggiarino previously served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career he held research and development positions at Angelini Pharmaceuticals, a private company, where he advanced to president of the firm, and Pharmacia Global R&D, where he was Clinical Program Director of Ophthalmology with responsibilities including Xalatan®, one of the leading glaucoma therapies in the world. Dr. Paggiarino earned his degree in Medicine and General Surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.

Mr. Ross has served as pSivida’s Vice President of Finance since November 2009, before which he spent 3 years as Corporate Controller. Mr. Ross was designated as the Company’s Principal Financial and Accounting Officer in March 2009. Mr. Ross is the former Corporate Controller of NMT Medical, Inc. and previously served as Vice President of Finance and Vice President of International Operations for JetForm Corporation. Mr. Ross brings 30 years of accounting and financial management experience to the Company. Mr. Ross received a Bachelor of Science degree in Chemical Engineering from Tufts University and an MBA from the Amos Tuck School at Dartmouth College.

Mr. Nazzaro has over 20 years of product life cycle and operations experience and has served as the Company’s Vice President of Operations since November 2009, having previously served as Director of Operations from May 2006 to November 2009. Mr. Nazzaro is the former Director of Manufacturing for Control Delivery Systems, Inc (CDS), a predecessor of pSivida US, Inc. Prior to CDS, Mr. Nazzaro held a variety of positions with Boston Scientific Corporation including responsibilities in logistics, R&D, manufacturing, and distribution, including responsibility for the distribution of cardiac care devices. Mr. Nazzaro received a Bachelor of Science degree in Accounting from Suffolk University in Boston, MA.

Dr. Riedel joined pSivida in October 2011, bringing with him over 29 years of biopharmaceutical R&D experience. Dr. Riedel has contributed significantly to the achievement of regulatory approval of several novel product candidates, including: INFUSE® (dibotermin alfa); Plenaxis® (abarelix), and the first generic version of Lovenox® (enoxaparin sodium). Dr. Riedel previously served as Vice President, Regulatory Affairs and Program Management at NormOxys, Inc., as Vice President of Regulatory Affairs at Momenta Pharmaceuticals, and as Senior Vice President of Regulatory Affairs, Quality Assurance and Project Management at PRAECIS Pharmaceuticals, Inc. Before joining PRAECIS, Dr. Riedel held various senior R&D positions at Wyeth Research and Genetics Institute, Inc. Dr. Riedel received a B.A. degree in Biochemical Sciences from Harvard College and a Ph.D. in Biology from Harvard University.

Board of Directors

Dr. Mazzo is the Chief Executive Officer and a Director at Caladrius Biosciences. Prior to joining Caladrius (formerly NeoStem), Dr. Mazzo served as Chief Executive Officer and as Director of Regado Biosciences, a company focused on the development of novel anti-thrombotic drug systems for acute and sub-acute cardiovascular indications. Dr.Mazzo was also Chief Executive Officer and Director of Aeterna Zentaris, Inc. and Chief Executive Officer and Director at Chugai Pharma USA LLC, a biopharmaceutical company. Dr. Mazzo has also held senior management and executive positions in research and development and was a Director of the Essex Chimie European subsidiary at Schering-Plough Corporation. Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in Chemistry and his Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst.

Nancy Lurker was appointed pSivida’s President & Chief Executive Officer in September 2016. Ms. Lurker has broad-ranging experience in the pharmaceutical industry and companies serving the pharmaceutical industry, including diverse senior leadership positions. From 2008 to 2015, Ms. Lurker served as President, Chief Executive Officer, and a director of PDI, Inc., a NASDAQ-listed healthcare commercialization company. She successfully rebuilt PDI’s contract sales business, launching numerous pharmaceutical products for multiple companies across diverse therapeutic areas, including ophthalmology, in advance of a sale of that business line to Publicis Healthcare Communications Group. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a multi-billion-dollar product portfolio covering cardiovascular, bone, pain, urology, respiratory, dermatology, biologics, neurology, and metabolic therapeutic areas. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company, now part of IMS Health Holdings, Inc., where she substantially grew revenues and profitability. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory, and women’s health drugs, overseeing the worldwide launch of Detrol® and Detrol® LA, and repositioning Ambien® for revenue growth. She also served as a member of Pharmacia’s U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker serves as a member of the Board of Directors of the privately held Cancer Treatment Centers of America, is Chair for privately held X4 Pharmaceuticals, an immunology oncology company and advisor to Novo A/S. Ms. Lurker previously served as a member of the Boards of Directors of Mallinckrodt Pharmaceuticals, plc (NYSE: MNK) and Auxilium Pharmaceuticals, Inc. (NASDAQ: ENDP). Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

Mr. Rogers brings significant financing, acquisition, investment banking, and partnering experience relating to pharmaceutical and biotech companies to the pSivida Board of Directors and is the Chairman of the pSivida Audit.  Mr. Rogers is the former Chief Financial Officer of Acorda Therapeutics, Inc., a biotechnology company focused on neurological disorders. Prior to Acorda, Mr. Rogers served as Executive Vice President and Chief Financial Officer of BG Medicine, Inc., a company focused on the development and commercialization of novel biomarker-based diagnostics, and Executive Vice President, Chief Financial Officer and Treasurer of Indevus Pharmaceuticals Inc., a specialty pharmaceutical company. He was also Executive Vice President and Chief Financial and Corporate Development Officer at Advanced Health Corporation, a healthcare information technology company, Vice President, Chief Financial Officer, and Treasurer of AutoImmune, Inc., a biopharmaceutical company, and Vice President, Investment Banking at Lehman Brothers, Inc. and PaineWebber, Inc.

Doug Godshall brings to pSidiva extensive experience and expertise in the medical device area. He was most recently the Chief Executive Officer and a Director of HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure. Under Mr. Godshall’s leadership, HeartWare was acquired by Medtronic in a deal valued at over $1 billion. Mr. Godshall joined HeartWare in 2006 from Boston Scientific Corporation where he worked for 16 years in various executive and leadership positions including President of the Vascular Surgery Division. He was also a member of Boston Scientific’s Operating Committee, and served as Vice President, Business Development where he oversaw more than 70 transactions including several strategic investments in the Ophthalmology arena.

Dr. Barry is the Executive Vice President and Chief Operating Officer and a director of InspireMD, a global medical device company focused on the development and commercialization of cardiovascular products. Dr. Barry has also been a Principal at Convergent Biomedical Group and served as President, CEO, and a director of Arsenal Medical and in various executive and managerial positions at Boston Scientific Corporation. Dr. Barry is also a director of AgNovos Healthcare LLC. Dr. Barry’s significant experience developing products, leading research and development teams, and building successful businesses, coupled with his expertise in advising clients in the pharmaceutical, biotechnology, and medical device industries, brings valuable technical expertise and commercial experience to pSivida.

As chairman of ophthalmology for Tufts Medical Center, Dr. Duker is responsible for managing the hospital’s clinical ophthalmology practice. His role as chairman of ophthalmology for Tufts University School of Medicine encompasses leading the academic mission of the school; educating medical students, residents, fellows, and practicing eye-care providers in ophthalmology; and conducting ophthalmic research. As the Director of the New England Eye Center, he leads an academic, multi-specialty eye care group with 35 ophthalmologists and nearly 200 employees. In his clinical practice, Dr. Duker treats diseases of the posterior segment of the eye including age-related macular degeneration (AMD), diabetic retinopathy, posterior segment uveitis, and retinal vascular diseases as well as rare retinal disorders. His principal research interests include retinal vascular disease, drug delivery to the eye, posterior uveitis, and novel imaging techniques for the posterior segment. He has published nearly 200 peer-reviewed journal articles and authored four books on ophthalmology including a best-selling textbook. Dr. Duker serves on the editorial board of three ophthalmic journals. He is a graduate of Harvard University and Jefferson Medical College. Dr. Duker is also a Director of Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, and a co-founder and Director of Hemera Biosciences, a privately held company seeking to develop anti-complement gene based therapies for the treatment of dry and wet age-related macular degeneration.

Partnerships

pSivida has successfully created partnerships with some of the world’s leading pharmaceutical companies. pSivida seeks additional strategic partners to collaborate on the development of new sustained-release bioerodible drug devices; to access complementary research, technology and development capabilities; and to expand our product portfolio.

pSivida’s technologies have broad applicability across many therapeutic areas. Our validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. pSivida’s intellectual property portfolio consists of our proven Durasert™ Technology platform for the delivery of small molecules and our preclinical stage Tethadur™ platform for large molecules such as antibodies and other proteins.